• 400+
    Pharmaceutical Partners
  • 150+
    Biomarker Assays
  • 300+
    Method Validations
  • 40+
    CDx

Clinical Testing

Patient Testing for Precision Medicine

  • Pan solid tumor
    Meet the diverse demands from clinicians and patients, MEDx Translational Medicine (MEDx) has developed a series of solid tumor tests, including pan-cancer gene panel tests, single cancer gene panel assays, and immunohistochemistry (IHC).
  • Hematologic Malignancy
    Most recently, molecular diagnostic products using PCR and next-generation sequencing (NGS) have significantly improved the understanding of molecular mechanism of hematological malignancies, leading to the right choice of molecular targeting drugs for precision therapy for the individual patients in clinic.
  • Infectious Disease
    Infectious Disease

About MEDx

Translational Medicine

MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.


Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient  stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.

view more >>

Events

Welcome to visit the MEDx Booth at Medlab Middle East 2024

Time:5-8 February, 2024Address:Dubai World Trade CentreMEDx Booth No: # Z2.H19We are honored

Meet MEDx at Medlab Middle East | Dubai 2024
On series |PIK3CA gene mutation and targeted therapy

Introduction The study of cancer has been extended from single genes to macrogenes, and from sing

MEDx and illumina jointly promote gene sequencing technology to help global new drug research

In the development process of innovative drugs, the accompanying diagnosis is like a indicating lamp

MEDx's Debut at 2023 Medlab Asia & Asia Health a Complete Success

From August 16 to 18, MEDx participated in the 2023 MedLab Asia held at the IMPACT Exhibition Centre

MEDx Partners with Junshi Biosciences in the Innovative Co-Development of Companion Diagnostics

On May 22, 2023, Shanghai Junshi Biosciences Co., Ltd. (hereinafter referred to as "Junshi Bios

HRD Panel of MEDx

Homologous Recombination Repair (HRR) and Poly ADP-ribose Polymerase (PARP) Repair are two important

MEDx Obtained the Global Authorization of Abcam

MEDx announced the expansion of global cooperation with its strategic partner Abcam (AIM:ABC; NASDAQ

Machine Learning Can Spot Tumor-Reactive TCRs, Speed Immunotherapies

Source: NIH, NIAIDThe manufacturing process for personalized T-cell therapies hardly begins before i

CAR T Cells Target Two Proteins, Shrink Brain Tumors in Phase I Trial

Human brain with tumor, 3D illustration. [Peterschreiber.media/Getty Images]Early results from an on

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will present findings from precli

U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib

Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Fo

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment

Poseida Therapeutics, Inc. a clinical-stage cell and gene therapy company advancing a new class of t

Pancreatic Cancer Drug Candidate Targets Elusive, but Common, K-Ras Variant

Credit: NIHK-Ras mutations are all too familiar as drivers of cancer. And until recently, they were

AI Drives Work on Pulmonary Fibrosis Drug from Target Discovery to Phase II

Credit: Just_Super / iStock / Getty Images PlusSome say that AI’s potential in drug development is

FDA Adcomm to Tackle Complexity of CAR-T for Multiple Myeloma

Pictured: Concept of FDA meeting collage/Nicole Bean for BioSpaceOn March 15, the FDA’s Oncologic D

Show of MEDx by CCTV